VIVALDI BIOSCIENCES TO PRESENT DATA ON COVID/INFLUENZA NASAL SPRAY VACCINE AT AMERICAN SOCIETY FOR VIROLOGY ANNUAL MEETING

FORT COLLINS, Colorado and VIENNA, Austria – July 13, 2022 – Vivaldi Biosciences, a clinical-stage biotechnology company developing nasal spray vaccines for viral respiratory diseases, today announced that the company will present data on its Delta-19 intranasal combination vaccine for Covid-19 and universal influenza at the Annual Meeting of the American Society for Virology in Madison, Wisconsin on July 17.

Delta-19 is composed of genetically modified live attenuated vaccine strains that express immunogenic antigens of SARS-CoV-2 (the virus responsible for Covid-19) and influenza viruses. The poster presentation will provide data on the development of Delta-19 and preclinical data demonstrating high levels of neutralizing antibodies for SARS-CoV-2 and influenza antigens, and protection against wild-type challenge in the ferret model.

Details of the presentation are as follows:

Presentation Title: Development of a SARS-CoV-2/Influenza Live Attenuated Intranasal Vaccine
Authors: Alaura Hoag, Matthew Baer, Amy Aspelund, Markus Wolschek, Manfred Reiter, and Thomas Muster
Presenting Author: Alaura Hoag, Vivaldi Biosciences
Date: July 17, 2022
Time: 8:30 pm CDT
Session / Location: P15, Exhibit Hall B

About Vivaldi Biosciences

Vivaldi Biosciences develops genetically engineered intranasal vaccines for epidemic and pandemic viral respiratory diseases. The company’s lead vaccine candidates are its DeltaFLU universal influenza vaccine in Phase 2 clinical development, and Delta-19 combination Covid-19 and universal influenza vaccine in preclinical development. Vivaldi Biosciences’ vaccine candidates are based on the company’s proprietary Delta NS1 technology platform. Delta NS1 is a vaccine vector based on genetically modified influenza virus strains. Delta NS1 vaccine strains are replication-deficient and unable to form viral progeny, which makes them safe. Vivaldi Biosciences has developed a rapid, high-yield Vero-cell based manufacturing system and produced Delta NS1 vaccines under cGMP for clinical trials. Vivaldi Biosciences is a venture-backed company with operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado, and in Vienna, Austria. NGN Capital LLC is the company’s lead investor. Learn more at www.vivaldibiosciences.com, and connect with Vivaldi Biosciences on LinkedIn.

Contact

Bill Wick, CEO, Vivaldi Biosciences
Tel: +1 650-400-8915
Forward-Looking Statements

This release contains forward-looking statements relating to Vivaldi Biosciences, which are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this communication concerning activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the following: the uncertainty of clinical success and of obtaining regulatory approvals, the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, product efficacy or safety concerns resulting in product recalls or regulatory action, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the ability to obtain future funding and to obtain such funding on commercially reasonable terms, the regulatory environment and other risks the Company may identify from time to time in the future. These factors are not necessarily all of the important factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. These forward-looking statements speak only as of the date of this communication and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. This press release should not constitute an offer to sell or a solicitation of an offer to buy securities.